Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Earnings

Mentari leans on about $50M related-party loan as losses reach $63M

Unaudited filings show Mentari burning through cash this year, with affiliated lending covering much of the gap and an accounting entry hinting at a possible share sale.

16 Nov 2026 · InMed Pharmaceuticals Inc. INM · Company news

Mentari Therapeutics lost $63.0 million over the first nine months of 2026, according to unaudited financial statements published through InMed Pharmaceuticals Inc. The third quarter accounted for $32.2 million of that, meaning roughly half of the nine-month deficit was incurred in the latest three months.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): InMed Pharmaceuticals Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More EarningsAll →